Can Twist Bioscience (TWST) Stock Reach $195?

Twist Bioscience Corporation (TWST) is a synthetic biology and genomics company that manufactures synthetic DNA using a proprietary silicon-based platform, serving customers in drug discovery, next-generation sequencing (NGS), and DNA data storage. After a dramatic run, the question investors are asking is whether the stock can extend toward a $195 target. That figure is not a single analyst's call; it is the average of the six current analyst price targets that sit above the latest market price.

Key Takeaways

• The $195 central target is the arithmetic mean of six verified analyst targets above the current price, roughly 35% above the latest close of about $144.49.
• Analyst targets are unusually dispersed, from about $41 to $215; the overall average of roughly a dozen reviewed targets is near $142, below the current price.
• Recent target raises reflect AI-enabled drug discovery momentum, led by Barclays ($215), Guggenheim ($212), Canaccord Genuity ($205), TD Cowen ($190) and Leerink Partners ($190).
• The bull case rests on roughly 20% revenue growth, gross margins above 50%, and a path to adjusted EBITDA breakeven by the end of fiscal 2026.
• Key risks are a lack of GAAP profitability, a rich valuation after a roughly 500% surge over the past year, and bearish outliers such as BWS Financial ($45) and Stephens ($41).

Analyst Price Targets and Consensus View

Because the stock has risen so far, so fast, many targets now lag the share price, which is why the full range matters as much as any single number. Reviewing a dozen attributable targets produces a range from roughly $41 to $215 and an overall average near $142 — below the latest price. Six targets remain above the current price: Barclays raised to $215 (October 7), Guggenheim to $212 (October 1), Canaccord Genuity to $205 (October 12), TD Cowen to $190 (October 13), Leerink Partners to $190, and Jefferies, which initiated at $150 with a Hold (October 8). Their average is about $194, rounded to a $195 central target. This is the average of above-price targets, not an official consensus, and the wide $41–$215 dispersion shows genuine disagreement about valuation.

The bulls argue the AI-driven drug-discovery opportunity is being underappreciated, while bears such as BWS Financial and Stephens contend the recent run already prices in far more than the fundamentals justify. Evercore ISI downgraded the stock to In Line in July even while raising its target, citing valuation after a very strong rally.

Current Market Position and Path Toward the Target

At a latest close of roughly $144.49, reaching $195 implies a move of about 35% — substantial for most stocks, though modest relative to the volatility Twist has already shown. The stock surged roughly 500% over the past year, touching multi-year highs near $189–$190 in early October before pulling back. Twist is not yet profitable on a GAAP basis, so the stock trades on growth and future profitability rather than earnings multiples.

The path toward a higher target depends on execution: sustaining above-50% gross margins, converting revenue growth into adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) breakeven, and delivering on AI-driven order growth.

What Could Support a Move Toward the Target

• Fiscal 2025 revenue rose 20% to $376.6 million, with gross margin expanding to 50.7%.
• Management raised fiscal 2026 revenue guidance to roughly $456–$457 million and targets adjusted EBITDA breakeven by the fourth quarter of fiscal 2026.
• Orders from AI-enabled drug-discovery projects grew more than $25 million in fiscal 2025, with commentary pointing to triple-digit growth in 2026 and 2027.
• Recent analyst upgrades and target raises have clustered around the AI discovery theme, reinforcing bullish sentiment.

What Could Prevent the Target From Being Reached

• The company remains unprofitable on a GAAP basis, with a fiscal 2025 net loss of $77.7 million.
• Valuation is rich after a parabolic rise; a re-rating lower could occur if growth or margin progress disappoints.
• Bearish targets ($45, $41) and insider selling flag concerns that enthusiasm may exceed fundamentals.
• The company has flagged near-term NGS revenue variability, including an "air pocket" tied to a customer transition.
• The shares are highly volatile; a roughly 20% drawdown from recent highs occurred within days.

Technical Levels and Market Structure

The shares set multi-year highs near $189–$190 in early October, making that zone a nearby resistance area that aligns with several recently raised targets. The $150 round-number level, matching Jefferies' initiation target, may act as a psychological marker on the way up. With the stock down more than 20% from its recent peak, the mid-$140s area has become a near-term focal point, though rapidly shifting momentum makes durable support levels difficult to pin down.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms differ and Twist's volatility means targets can change quickly. Investors should monitor quarterly earnings and guidance, gross-margin trends, progress toward adjusted EBITDA breakeven, AI-enabled drug-discovery order growth, any new partnerships or equity offerings, and analyst revisions. Given the stock's sensitivity to AI narratives, sector sentiment and any regulatory or competitive developments in AI-driven drug discovery also matter.

AI Daily Buy/Sell Signals

For traders seeking an objective, data-driven view amid this volatility, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how AI can sharpen your daily decision-making.

Final Assessment

The $195 central target is the average of the six analyst targets above the current price and represents roughly 35% upside from about $144.49. The strongest supports are durable revenue growth, expanding gross margins, an approaching adjusted EBITDA breakeven, and rapidly growing AI-driven drug-discovery orders. The principal obstacles are the absence of GAAP profitability, a stretched valuation after an extraordinary run, and a wide analyst range — from $41 to $215 — that underscores how divided the Street is. Whether the stock reaches $195 will depend on consistent execution and sustained AI momentum, not on any single forecast. Investors should weigh the growth narrative against the valuation risk and monitor upcoming earnings and guidance closely.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations